Back to Journals » Patient Preference and Adherence » Volume 13

Patient attitudes toward and goals for MDD treatment: a survey study

Authors McNaughton EC, Curran C, Granskie J, Opler M, Sarkey S, Mucha L, Eramo A, François C, Webber-Lind B, McCue M

Received 5 February 2019

Accepted for publication 13 April 2019

Published 14 June 2019 Volume 2019:13 Pages 959—967

DOI https://doi.org/10.2147/PPA.S204198

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Johnny Chen


Emily C McNaughton,1 Christopher Curran,1 Jamie Granskie,1 Mark Opler,2 Sara Sarkey,3 Lisa Mucha,3 Anna Eramo,4 Clement François,4 Briana Webber-Lind,5 Maggie McCue3

1Research Department, PatientsLikeMe,® Cambridge, MA, USA; 2MedAvante Prophase, New York, NY, USA; 3Medical Affairs, Takeda Pharmaceuticals U.S.A, Deerfield, IL, USA; 4US Clinical and Medical Affairs, Lundbeck LLC, Deerfield, IL, USA; 5Department of Clinical Science, MedAvante Prophase, Charlotte, NC, USA

Background/Objectives: Major depressive disorder (MDD) is a highly prevalent disorder, frequently diagnosed and treated in a primary care setting; however, little information is available about the treatment decision-making process between MDD patients and their providers. A shared decision-making and goal attainment approach to establishing and tracking progress toward treatment goals that are meaningful to individual patients is explored in this survey study. In addition, information about patient perspectives on setting treatment goals, medication selection/switching, and engaging patients with their health care professionals was also collected and evaluated.
Methods: A 50-question online survey was administered to members of the PatientsLikeMe community who indicated an MDD diagnosis and a switch in antidepressant medications within the past 2 years. Follow-up interviews were also conducted with a small subset of these participants.
Results: Of the 200 participants who completed the survey, 42% reported currently having goals for MDD treatment. These goals were typically in the areas of physical health (62.7%), cognitive functioning (60.2%), and social aspects of life (57.8%). A majority of survey participants (61%) believed the goal attainment approach would be helpful to set and evaluate treatment goals.
Conclusions: The data provide important insights into patient perspectives on the development of formal treatment plans and goals for MDD. In addition, the data also support the use of a patient-centric approach to shared decision-making by using a goal attainment scale to establish and track progress toward treatment goals that are meaningful to MDD patients in real-world clinical practice. The results of this study can be used to inform best practices in patient–clinician communication when developing an MDD treatment plan and goals.

Keywords: goal attainment scale (GAS), PatientsLikeMe, treatment goals, depression, antidepressant, patient-centric


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]